PureTech's deupirfenidone demonstrated potential to stabilize lung function decline over 26 weeks in idiopathic pulmonary fibrosis patients, an unprecedented achievement in IPF treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.